Related references
Note: Only part of the references are listed.Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
Stefan Schreiber et al.
GASTROENTEROLOGY (2021)
Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration
Deepa Denesh et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
Ajay M Verma et al.
Lancet Gastroenterology & Hepatology (2021)
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Nicholas A. Kennedy et al.
GUT (2021)
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic
Nicholas A. Kennedy et al.
FRONTLINE GASTROENTEROLOGY (2020)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher Andrew Lamb et al.
GUT (2019)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
Gert Van Assche et al.
GUT (2012)
Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2012)
When to use biological agents in inflammatory bowel disease
Crispin Corte et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
How do patients with inflammatory bowel disease want their biological therapy administered?
Patrick B. Allen et al.
BMC GASTROENTEROLOGY (2010)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)